Skip to main content

Table 2 Change in ADAS-Cog scores

From: Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study

Day 45 Change from Baseline

      

Gene

SNP/Allele

Genotype

AC1202

n

Placebo

n

p-value*

Difference (CI)

APOE

APOE

3/2

-1.222

3

5.167

2

0.182

6.389(-3.050, 15.828)

APOE

APOE

3/3

-2.317

20

2.999

23

0.001

5.315(2.154, 8.476)

APOE

APOE

4/2

2.778

3

.

0

na

na

APOE

APOE

4/3

1.107

28

2.175

19

0.492

1.068(-2.005, 4.142)

APOE

APOE

4/4

-1.667

3

-1.167

10

0.884

0.500(-6.306, 7.306)

IDE

rs2251101

C

2.375

8

-0.905

7

0.138

3.280(-1.076, 7.635)

IDE

rs2251101

Het

-1.647

17

2.317

23

0.004

3.964(1.273, 6.656)

IDE

rs2251101

T

-0.711

30

1.290

23

0.092

2.001(-0.331, 4.333)

IDE c/c

IDE c/c (-)

IDE -

-1.050

47

1.804

46

0.002

2.853(1.100, 4.606)

IDE c/c

IDE c/c (+)

IDE +

2.375

8

-0.905

7

0.140

3.280(-1.094, 7.654)

IL1B

rs1143627

C

1.000

5

2.481

9

0.545

1.481(-3.365, 6.328)

IL1B

rs1143627

Het

-1.097

24

-0.020

17

0.439

1.078(-1.677, 3.832)

IL1B

rs1143627

T

-0.768

23

2.026

24

0.031

2.795(0.259, 5.330)

IL1B

rs16944

C

-0.768

23

2.026

24

0.031

2.795(0.259, 5.330)

IL1B

rs16944

Het

-1.097

24

-0.020

17

0.439

1.078(-1.677, 3.832)

IL1B

rs16944

T

1.000

5

2.481

9

0.545

1.481(-3.365, 6.328)

Day 90 Change from Baseline

      

APOE

APOE

3/2

3.667

1

6.333

1

0.737

2.667(-13.098, 18.431)

APOE

APOE

3/3

-2.579

19

1.398

20

0.029

3.977(0.406, 7.548)

APOE

APOE

4/2

-3.667

2

.

0

na

na

APOE

APOE

4/3

1.302

21

0.471

17

0.651

0.831(-2.806, 4.468,)

APOE

APOE

4/4

1.667

2

0.867

10

0.854

0.800(-7.835, 9.435)

IDE

rs2251101

C

3.905

7

-1.857

7

0.047

5.762(0.074, 11.450)

IDE

rs2251101

Het

-2.769

13

2.944

19

0.004

5.713(1.883, 9.543)

IDE

rs2251101

T

-0.931

24

0.446

21

0.392

1.377(-1.803, 4.556)

IDE c/c

IDE c/c (-)

IDE -

-1.577

37

1.633

40

0.011

3.209(0.766, 5.652)

IDE c/c

IDE c/c (+)

IDE +

3.905

7

-1.857

7

0.049

5.762(0.038, 11.486)

IL1B

rs1143627

C

-1.083

4

1.815

9

0.396

2.898(-3.859, 9.656)

IL1B

rs1143627

Het

-0.193

19

-0.044

15

0.940

0.149(-3.735, 4.033)

IL1B

rs1143627

T

-1.947

19

1.748

20

0.044

3.696(0.093, 7.298)

IL1B

rs16944

C

-1.947

19

1.748

20

0.044

3.696(0.093, 7.298)

IL1B

rs16944

Het

-0.193

19

-0.044

15

0.940

0.149(-3.735, 4.033)

IL1B

rs16944

T

-1.083

4

1.815

9

0.396

2.898(-3.859, 9.656)

Day 104 Change from Baseline

      

APOE

APOE

3/2

-1.333

3

2.333

2

0.474

3.667(-6.443, 13.776)

APOE

APOE

3/3

-0.812

23

1.384

21

0.196

2.196(-1.147, 5.538)

APOE

APOE

4/2

0.889

3

.

0

na

na

APOE

APOE

4/3

0.821

26

-0.722

18

0.370

1.543(-1.853, 4.938)

APOE

APOE

4/4

-1.083

4

0.933

10

0.543

2.017(-4.535, 8.568)

IDE

rs2251101

C

3.762

7

0.952

7

0.331

2.810(-2.895, 8.514)

IDE

rs2251101

Het

-2.169

18

0.317

20

0.158

2.485(-0.982, 5.953)

IDE

rs2251101

T

-0.029

33

0.867

22

0.547

0.896(-2.042, 3.834)

IDE c/c

IDE c/c (-)

IDE -

-0.784

51

0.605

42

0.217

1.389(-0.828, 3.606)

IDE c/c

IDE c/c (+)

IDE +

3.762

7

0.952

7

0.330

2.810(-2.878, 8.497)

IL1B

rs1143627

C

0.778

6

0.407

9

0.898

0.370(-5.373, 6.114)

IL1B

rs1143627

Het

-0.376

24

0.524

14

0.627

0.900(-2.765, 4.565)

IL1B

rs1143627

T

-0.720

25

0.380

23

0.490

1.100(-2.049, 4.248)

IL1B

rs16944

C

-0.720

25

0.380

23

0.490

1.100(-2.049, 4.248)

IL1B

rs16944

Het

-0.376

24

0.524

14

0.627

0.900(-2.765, 4.565)

IL1B

rs16944

T

0.778

6

0.407

9

0.898

0.370(-5.373, 6.114)

  1. *p-value < 0.05 bold, < 0.01 bold and underlined. na = not available